About Us
Technology & Pipeline
Governance
Investors
Media
Contact

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

September 24, 2012

Annual General Meeting 2012

The Annual General Meeting of 2012 was held on September 24, 2012, at 4 p.m in Oasmias offices at Vallongatan 1, Uppsala, Sweden.

Documents

Notice of Annual General Meeting
English September 24, 2012
Documents at the Annual General Meeting 2012
English September 24, 2012
Reasoned Opinion
English 2012

Share this page

Calendar

November 21, 2024
Interim report Q3 2024
February 20, 2025
Year-end report 2024

Corporate Governance

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com